LakeShore Competitors
| LSBCF Stock | 0.06 0.01 11.76% |
LakeShore Biopharma vs XOMA Corp Correlation
Very weak diversification
The correlation between LakeShore Biopharma Co and XOMA is 0.43 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding LakeShore Biopharma Co and XOMA in the same portfolio, assuming nothing else is changed.
Moving together with LakeShore Stock
| 0.62 | NONOF | Novo Nordisk AS | PairCorr |
| 0.63 | NVO | Novo Nordisk AS | PairCorr |
| 0.72 | CSLLY | CSL | PairCorr |
| 0.67 | CMXHF | CSL Limited | PairCorr |
Moving against LakeShore Stock
| 0.93 | WF | Woori Financial Group | PairCorr |
| 0.92 | KB | KB Financial Group | PairCorr |
| 0.91 | SHG | Shinhan Financial | PairCorr |
| 0.7 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.6 | VRTX | Vertex Pharmaceuticals | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of LakeShore Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
LakeShore Biopharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between LakeShore Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of LakeShore and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of LakeShore Biopharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between LakeShore Stock performing well and LakeShore Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze LakeShore Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ADAG | 4.62 | 0.65 | 0.13 | 1.12 | 4.29 | 13.77 | 33.22 | |||
| ANRO | 3.68 | 0.80 | 0.16 | 2.20 | 4.16 | 7.87 | 23.67 | |||
| ASBP | 7.60 | (1.17) | 0.00 | (1.88) | 0.00 | 19.52 | 66.08 | |||
| BSEM | 6.99 | 0.72 | 0.10 | (0.57) | 5.88 | 21.04 | 48.13 | |||
| CANF | 5.27 | 0.16 | 0.01 | (0.05) | 6.84 | 10.40 | 38.42 | |||
| CGTX | 3.91 | (0.42) | 0.00 | 1.81 | 0.00 | 7.69 | 25.11 | |||
| MIRM | 2.14 | 0.39 | 0.10 | 0.78 | 3.26 | 5.97 | 25.74 | |||
| VXRT | 4.74 | 1.49 | 0.19 | (6.20) | 5.94 | 14.29 | 75.42 | |||
| VYGR | 2.58 | 0.03 | 0.02 | 0.05 | 2.93 | 5.59 | 19.71 | |||
| XOMA | 3.17 | (0.20) | 0.00 | (0.72) | 0.00 | 6.79 | 29.87 |
Cross Equities Net Income Analysis
Compare LakeShore Biopharma and related stocks such as Adagene, Alto Neuroscience, and Aspire BioPharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADAG | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.3 M) | (16.4 M) | (73.2 M) | (80 M) | (18.9 M) | (33.4 M) | (30.1 M) | (31.6 M) |
| ANRO | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (27.7 M) | (36.3 M) | (61.4 M) | (61.4 M) | (55.3 M) | (52.5 M) |
| ASBP | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | 3.3 M | 4.5 M | (12.5 M) | (11.3 M) | (10.7 M) |
| CANF | (3.7 M) | (6.7 M) | (5.6 M) | (8.3 M) | (6.1 M) | (4.8 M) | (6.9 M) | (5 M) | (6.6 M) | (12.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (7.6 M) | (7.9 M) | (7.1 M) | (7.4 M) |
| CGTX | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (10.1 M) | (11.7 M) | 757 K | (25.8 M) | (34 M) | (30.6 M) | (29 M) |
| MIRM | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (52.6 M) | (103.3 M) | (84 M) | (135.7 M) | (163.4 M) | (87.9 M) | (23.4 M) | (24.5 M) |
| VXRT | 1000 K | (4.5 M) | (8.7 M) | (8.9 M) | (11 M) | (19.1 M) | (25.4 M) | (12.5 M) | (18 M) | (18.6 M) | (32.2 M) | (70.5 M) | (107.8 M) | (82.5 M) | (66.9 M) | (60.3 M) | (57.2 M) |
| VYGR | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (16.3 M) | (29.7 M) | (40.2 M) | (70.7 M) | (88.3 M) | (40.8 M) | 36.7 M | (66 M) | (46.4 M) | 132.3 M | (65 M) | (74.8 M) | (71 M) |
| XOMA | (4.8 M) | (32.7 M) | (71.1 M) | (124.1 M) | (38.3 M) | (20.6 M) | (53.5 M) | 14.6 M | (13.3 M) | (2 M) | 13.3 M | 15.8 M | (17.1 M) | (40.8 M) | (13.8 M) | (15.9 M) | (16.7 M) |
LakeShore Biopharma and related stocks such as Adagene, Alto Neuroscience, and Aspire BioPharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in LakeShore Biopharma financial statement analysis. It represents the amount of money remaining after all of LakeShore Biopharma Co operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.LakeShore Biopharma Competitive Analysis
The better you understand LakeShore Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, LakeShore Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across LakeShore Biopharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
LakeShore Biopharma Competition Performance Charts
Five steps to successful analysis of LakeShore Biopharma Competition
LakeShore Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by LakeShore Biopharma in relation to its competition. LakeShore Biopharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of LakeShore Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact LakeShore Biopharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to LakeShore Biopharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your LakeShore Biopharma position
In addition to having LakeShore Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out LakeShore Biopharma Correlation with its peers. You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Can Biotechnology industry sustain growth momentum? Does LakeShore have expansion opportunities? Factors like these will boost the valuation of LakeShore Biopharma. Expected growth trajectory for LakeShore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating LakeShore Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding LakeShore Biopharma requires distinguishing between market price and book value, where the latter reflects LakeShore's accounting equity. The concept of intrinsic value - what LakeShore Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push LakeShore Biopharma's price substantially above or below its fundamental value.
Understanding that LakeShore Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LakeShore Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LakeShore Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.